Clinical trial • Phase III • Oncology|Gastroenterology
Clinical trial in Cholangiocarcinoma|Pancreatic cancer|Colorectal cancer
Phase III trial for Cholangiocarcinoma|Pancreatic cancer|Colorectal cancer. 20 participants.
Overview
- Trial Therapeutic Area
- Oncology|Gastroenterology
- Trial Disease
- Cholangiocarcinoma|Pancreatic cancer|Colorectal cancer
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 07-07-2025
- First CTIS Authorization Date
- 30-09-2025
Trial design
Phase III trial across 1 site in Sweden.
- Target Sample Size
- 20
- Trial Duration For Participant
- 1186
Recruitment
- Planned Sample Size
- 20
- Recruitment Window Months
- 39
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 20
Sweden
- Earliest CTIS Part Ii Submission Date
- 28-08-2025
- Latest Decision Or Authorization Date
- 30-09-2025
- Processing Time Days
- 33
- Number Of Sites
- 1
- Number Of Participants
- 20
Sites
- Site Name
- Karolinska University Hospital
- Department Name
- Nuclear medicine and hospital Physics
- Principal Investigator Name
- Antonios Tzortzakakis
- Principal Investigator Email
- antonios.tzortzakakis@ki.se
- Contact Person Name
- Antonios Tzortzakakis
- Contact Person Email
- antonios.tzortzakakis@ki.se
- Number Of Participants
- 20
Sponsor
Primary sponsor
- Full Name
- Karolinska University Hospital
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Sweden
Related trials
Other published trials that may interest you.
- Girentuximab (labelled with Zirconium-89) for Gastroenteropancreatic neuroendocrine neoplasms|Hepatocellular carcinoma|Biliary tract cancer
- DOSTARLIMAB for Resectable colon cancer (pMMR/MSS)
- D,L-LYSINE ACETYLSALICYLATE for Metastatic colorectal cancer|Chemo-resistant metastatic colorectal cancer
- BEVACIZUMAB for Advanced hepatocellular carcinoma|Liver transplant recipient
- Capecitabine for Gastric adenocarcinoma|Gastroesophageal junction adenocarcinoma